Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Priority Review erases Shire's losses on trial miss

Shire plc (LSE:SHP; NASDAQ:SHPG) turned early losses on clinical data into gains on Thursday, picking up $7.24 to $254.32 on NASDAQ after FDA accepted for filing and granted Priority Review to an

Read the full 328 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers